Quintiles Named Best Contract Research Organization at SCRIP Awards for Third Consecutive Year
December 04 2014 - 8:00AM
Business Wire
Quintiles today announced that the company was awarded “Best
Contract Research Organization” at the annual SCRIP Awards for the
third year in-a-row. This is the company’s fourth award received in
this category in the last five years. The SCRIP Awards acknowledge
excellence in the biopharmaceutical industry, based on judging by
an independent panel of 12 life sciences experts.
Paula Brown Stafford, President, Clinical
Development, Quintiles (Photo: Business Wire)
“Our judges felt Quintiles was a worthy winner of the Best
Contract Research Organization trophy for the third year in a row,”
said Mike Ward, global director of content for IBI Pharma News
& Datamonitor Healthcare. “In the qualifying year, Quintiles
once again demonstrated a series of performance milestones in its
quest to improve its customers' probability of success. Among its
many accomplishments, Quintiles signed a series of transformational
partnerships and launched innovative technologies to improve trial
execution. Despite plenty of competition, Quintiles remains the CRO
to beat.”
Commenting on the award, Paula Brown Stafford, president of
Clinical Development at Quintiles said, “To be recognized for the
third straight year by SCRIP is a tremendous accomplishment. It
demonstrates the true impact that Quintiles has on improving our
customers’ probability of success and on the broader
biopharmaceutical industry. We are honored to receive this award,
and I would like to dedicate it to our employees around the world
who made all of our tremendous accomplishments this past year
possible.”
The tenth annual SCRIP awards ceremony was held in London and
was attended by industry leaders from around the world.
About Quintiles
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s
largest provider of biopharmaceutical development and commercial
outsourcing services. With a network of more than 32,000 employees
conducting business in approximately 100 countries, we helped
develop or commercialize all of 2013’s top-100 best-selling drugs
on the market. Quintiles applies the breadth and depth of our
service offerings along with extensive therapeutic, scientific and
analytics expertise to help our customers navigate an increasingly
complex healthcare environment as they seek to improve efficiency
and effectiveness in the delivery of better healthcare
outcomes. To learn more about Quintiles, please visit
www.quintiles.com
Click here to subscribe to Mobile Alerts for Quintiles.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20141204005177/en/
QuintilesMedia Relations:Mari Mansfield, 1-919-998-2639Mobile:
+1-919-259-3298mari.mansfield@quintiles.comorInvestor
Relations:Karl Deonanan,
+1-919-998-2789InvestorRelations@quintiles.com
Qimonda AG Ads (NYSE:QI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Qimonda AG Ads (NYSE:QI)
Historical Stock Chart
From Jul 2023 to Jul 2024